H.C. Wainwright raises Genmab stock price target on positive trial data
H.C. Wainwright raised its price target for Genmab (GMAB) to $50 from $40, citing positive Phase 3 trial results for EPKINLY. The stock is up 23% YTD. Genmab reported Q2 2026 earnings of $4.91 per share, beating estimates, and raised its 2026 revenue guidance. Guggenheim also increased its price target to $54.
How this was made
The 30-second read
Why it matters
The combined analyst target hikes and 51% risk reduction in the Phase 3 trial provide a catalyst for short‑term price appreciation.
Market read
First‑report of pivotal trial data and analyst target increase creates immediate trading interest in GMAB.
What to watch
Potential competition from other CD20‑targeted therapies and reimbursement uncertainties could temper upside.
Background
The article summarizes analyst upgrades and trial outcomes for Genmab, a Danish biotech listed on NASDAQ.
Ticker impact
H.C. Wainwright raised its price target on Genmab to $50 after positive Phase 3 EPCORE DLBCL-2 trial data.
likely upward as market prices in the improved efficacy data and higher target price
Target increase from $40 to $50 and 51% risk reduction in trial indicate material clinical progress, prompting buying interest.
Market effects
Positive biotech trial data may lift peer oncology stocks and reinforce confidence in late‑stage antibody therapies.
European biotech sector could see modest gains as a Danish‑listed firm reports strong results.
Adds to broader narrative of successful immuno‑oncology pipelines, supporting sector momentum.
Counterpoint
If the trial data fails to translate into regulatory approval or commercial uptake, the price target may be premature.
Key entities
- companyGenmab A/S
Danish biotech developing epcoritamab (EPKINLY) and other antibody therapies.
- analyst_firmH.C. Wainwright
Equity research firm that raised GMAB price target.
